CD34 and acute myeloid leukemia: Our study elucidated that the CD34+ CD38low/−CD123+ phenotype is present in a significant proportion of AML patients and it may be responsible for resistance to traditional treatments, and high percentage of MRD that is translated into significantly high number of non CR, poor DFS, and OS.